MSH|^~\&|BC-6800|Mindray|||20221015125007||ORU^R01|2|P|2.3.1||||||UNICODEPID|1||3803^^^^MR||KONATE^Djeneba|||FémininPV1|1||Pédiat-Cliniq-KABALAOBR|1||06 du 12/01/22|00001^Automated Count^99MRC|||20200812091920|||Dr Oumar COULIBALY||||||||||||||HM||||||||adminOBX|1|IS|08001^Take Mode^99MRC||O||||||FOBX|2|IS|08002^Blood Mode^99MRC||W||||||FOBX|3|IS|08003^Test Mode^99MRC||CBC+DIFF+RET+NRBC||||||FOBX|4|IS|01002^Ref Group^99MRC||Enfant||||||FOBX|5|NM|30525-0^Age^LN||18|mo|||||FOBX|6|IS|05007^Project Type^99MRC||BL||||||FOBX|7|IS|01007^Sample Type^99MRC||EDTA||||||FOBX|8|ST|09001^Analyzer^99MRC||BC-6800||||||FOBX|9|NM|6690-2^WBC^LN||7.78|10*9/L|4.00-12.00|A|||FOBX|10|NM|704-7^BAS#^LN||0.02|10*9/L|0.00-0.10|A|||FOBX|11|NM|706-2^BAS%^LN||0.3|%|0.0-1.0|A|||FOBX|12|NM|751-8^NEU#^LN||5.34|10*9/L|2.00-8.00|A|||FOBX|13|NM|770-8^NEU%^LN||68.7|%|50.0-70.0|A|||FOBX|14|NM|711-2^EOS#^LN||0.05|10*9/L|0.02-0.80|A|||FOBX|15|NM|713-8^EOS%^LN||0.6|%|0.5-5.0|A|||FOBX|16|NM|731-0^LYM#^LN||1.71|10*9/L|0.80-7.00|A|||FOBX|17|NM|736-9^LYM%^LN||21.9|%|20.0-60.0|A|||FOBX|18|NM|742-7^MON#^LN||0.66|10*9/L|0.12-1.20|A|||FOBX|19|NM|5905-5^MON%^LN||8.5|%|3.0-12.0|A|||FOBX|20|NM|789-8^RBC^LN||4.17|10*12/L|3.50-5.20|N|||FOBX|21|NM|718-7^HGB^LN||11.2|g/dL|12.0-16.0|L~N|||FOBX|22|NM|787-2^MCV^LN||84.6|fL|80.0-100.0|N|||FOBX|23|NM|785-6^MCH^LN||26.9|pg|27.0-34.0|L~N|||FOBX|24|NM|786-4^MCHC^LN||31.8|g/dL|31.0-37.0|N|||FOBX|25|NM|788-0^RDW-CV^LN||1